Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Int J Antimicrob Agents. 2020 Nov 6;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220

TABLE 1.

LONG ACTING DRUGS IN DEVELOPMENT FOR HIV PREVENTION AND TREATMENT BY INFUSION, INJECTION OR IMPLANT

ARV Class Agent Formulation Development Stage
NRTI Islatravir (MK-8591) Implant Phase I
TAF Implant Phase I/II (Px)
GS-9131 Implant Preclinical
NNRTI Rilpivirine Injectable Phase III/NDA
Elsulfavirine Injectable Preclinical
PI Atazanavir Injectable Preclinical
Ritonavir Injectable Preclinical
INSTI Cabotegravir Injectable Phase III/NDA, Phase II/III (Px)
Dolutegravir Implant Preclinical (Px)
Raltegravir Injectable Preclinical
Entry Inhibitors Ibalizumab Intravenous FDA Approved (Tx)
Leronlimab (PRO 140) Intravenous and Injectable Phase III
Albuvirtide Intravenous and injectable Approved in China
bNAbs (e.g., VRC01, VRC07) Intravenous Phase I/II/III
Combinectin Intravenous Phase I
Capsid Inhibitors GS-6207 Injectable Phase II

ARV = antiretroviral; Px = prevention; Tx = treatment